BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 19123460)

  • 1. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases.
    Bussone G; Ribeiro E; Dechartres A; Viallard JF; Bonnotte B; Fain O; Godeau B; Michel M
    Am J Hematol; 2009 Mar; 84(3):153-7. PubMed ID: 19123460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.
    Peñalver FJ; Alvarez-Larrán A; Díez-Martin JL; Gallur L; Jarque I; Caballero D; Díaz-Mediavilla J; Bustelos R; Fernández-Aceñero MJ; Cabrera JR;
    Ann Hematol; 2010 Nov; 89(11):1073-80. PubMed ID: 20526716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
    J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients.
    D'Arena G; Califano C; Annunziata M; Tartarone A; Capalbo S; Villani O; Amendola G; Pietrantuono G; Ferrara F; Pinto A; Musto P; D'Arco AM; Cascavilla N
    Eur J Haematol; 2007 Jul; 79(1):53-8. PubMed ID: 17532766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.
    Maung SW; Leahy M; O'Leary HM; Khan I; Cahill MR; Gilligan O; Murphy P; McPherson S; Jackson F; Ryan M; Hennessy B; McHugh J; Goodyer M; Bacon L; O'Gorman P; Nee A; O'Dwyer M; Enright H; Saunders J; O'Keeffe D
    Br J Haematol; 2013 Oct; 163(1):118-22. PubMed ID: 23909468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy for childhood-onset systemic lupus erythematosus.
    Willems M; Haddad E; Niaudet P; Koné-Paut I; Bensman A; Cochat P; Deschênes G; Fakhouri F; Leblanc T; Llanas B; Loirat C; Pillet P; Ranchin B; Salomon R; Ulinski T; Bader-Meunier B;
    J Pediatr; 2006 May; 148(5):623-627. PubMed ID: 16737873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults.
    Provan D; Butler T; Evangelista ML; Amadori S; Newland AC; Stasi R
    Haematologica; 2007 Dec; 92(12):1695-8. PubMed ID: 18055995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in the treatment of refractory autoimmune cytopenias in adults.
    Narat S; Gandla J; Hoffbrand AV; Hughes RG; Mehta AB
    Haematologica; 2005 Sep; 90(9):1273-4. PubMed ID: 16154853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rituximab instead of splenectomy in 4 children with chronic or refractory autoimmune haemolytic anaemia].
    van Daalen ST; van Dijken PJ; Tamminga RY; Brons PP
    Ned Tijdschr Geneeskd; 2005 Oct; 149(42):2350-4. PubMed ID: 16261716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology.
    Dungarwalla M; Marsh JC; Tooze JA; Lucas G; Ouwehand W; Pettengell R; Dearden CE; Gordon Smith EC; Elebute MO
    Ann Hematol; 2007 Mar; 86(3):191-7. PubMed ID: 17123083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The long-term efficacy and safety of rituximab combined with cyclophosphamide in treatment of seven patients with refractory and recurrent autoimmune hemolytic anemia].
    Liu H; Xing LM; Wang HQ; Wu YH; Qu W; Liang Y; Wang GJ; Song J; Wang XM; Guan J; Li LJ; Fu R; Shao ZH
    Zhonghua Nei Ke Za Zhi; 2012 Jun; 51(6):456-9. PubMed ID: 22943757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Delayed response to rituximab of cold agglutinin haemolytic disease].
    Calvo-Villas JM; Cuesta Tovar J; Carreter de Granda E; Sicilia Guillén F
    An Med Interna; 2006 May; 23(5):224-8. PubMed ID: 16817700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.
    Rao A; Kelly M; Musselman M; Ramadas J; Wilson D; Grossman W; Shenoy S
    Pediatr Blood Cancer; 2008 Apr; 50(4):822-5. PubMed ID: 17570702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
    Kumar S; Benseler SM; Kirby-Allen M; Silverman ED
    Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient.
    Gentile M; Lucia E; Iorio C; Vigna E; Mazzone C; Morelli R; Bisconte MG; Gentile C; Morabito F
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):741-3. PubMed ID: 18064461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab.
    Ramanathan S; Koutts J; Hertzberg MS
    Am J Hematol; 2005 Feb; 78(2):123-6. PubMed ID: 15682420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients.
    Roumier M; Loustau V; Guillaud C; Languille L; Mahevas M; Khellaf M; Limal N; Noizat-Pirenne F; Godeau B; Michel M
    Am J Hematol; 2014 Sep; 89(9):E150-5. PubMed ID: 24847759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency.
    Kim JJ; Thrasher AJ; Jones AM; Davies EG; Cale CM
    Br J Haematol; 2007 Jul; 138(1):94-6. PubMed ID: 17498197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
    El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
    J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
    D'Arena G; Laurenti L; Capalbo S; D'Arco AM; De Filippi R; Marcacci G; Di Renzo N; Storti S; Califano C; Vigliotti ML; Tarnani M; Ferrara F; Pinto A
    Am J Hematol; 2006 Aug; 81(8):598-602. PubMed ID: 16823816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.